L. Mcdermott

发表

Trends in antimicrobial resistance among Bacteroides species and Parabacteroides species in the United States from 2010-2012 with comparison to 2008-2009.

D. Snydman, Robin Patel, E. Goldstein, 2017, Anaerobe.

Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin

D. Snydman, S. Walk, L. Mcdermott, 2018, The Journal of antimicrobial chemotherapy.

In Vitro Evaluation of the Activity of Aztreonam-Avibactam against 341 Recent Clinical Isolates of Anaerobes

D. Snydman, L. Mcdermott, L. McDermott, 2021, Microbiology spectrum.

U.S.-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016

D. Snydman, B. A. Forbes, D. Gerding, 2019, Antimicrobial Agents and Chemotherapy.

Evaluation of the In Vitro Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates

D. Snydman, T. Grossman, N. Jacobus, 2018, Antimicrobial Agents and Chemotherapy.

Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007).

D. Snydman, J. Rosenblatt, V. Yu, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern?

F. Marty, D. Kontoyiannis, David A. Oxman, 2010, The Journal of antimicrobial chemotherapy.

Epidemiologic trends in Clostridioides difficile isolate ribotypes in United States from 2011 to 2016.

D. Snydman, B. A. Forbes, D. Gerding, 2020, Anaerobe.

U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin

D. Snydman, B. A. Forbes, D. Gerding, 2015, Antimicrobial Agents and Chemotherapy.

A repeat offender: Recurrent extraintestinal Clostridium difficile infection following fecal microbiota transplantation.

D. Snydman, S. Walk, L. Mcdermott, 2018, Anaerobe.

Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial.

D. Snydman, V. Yu, L. Mcdermott, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Evaluation of the in vitro activity of NVP-LMB415 against clinical anaerobic isolates with emphasis on the Bacteroides fragilis group.

D. Snydman, N. Jacobus, L. Mcdermott, 2005, The Journal of antimicrobial chemotherapy.

National survey on the susceptibility of Bacteroides Fragilis Group: report and analysis of trends for 1997-2000.

D. Snydman, R. Venezia, E. Goldstein, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Multicenter Study of In Vitro Susceptibility of theBacteroides fragilis Group, 1995 to 1996, with Comparison of Resistance Trends from 1990 to 1996

D. Snydman, S. Gorbach, S. Jenkins, 1999, Antimicrobial Agents and Chemotherapy.

Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994.

D. Snydman, V. Yu, S. Gorbach, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients.

D. Snydman, L. Mcdermott, José A. Martínez, 2002, The Journal of antimicrobial chemotherapy.